Burdelski M M
Universitätsklinikum Hamburg-Eppendorf, Department of Pediatrics, Hamburg, Germany.
Transplant Proc. 2004 Mar;36(2 Suppl):295S-298S. doi: 10.1016/j.transproceed.2003.12.027.
Since the introduction of cyclosporine into pediatric liver transplantation remarkable progress in patient and graft survival has been observed: survival rates 60%; acute (60%), steroid-resistant (22%) and chronic rejection (4%); infections (60%); and side effects (20%). Individualization of cyclosporine therapy complements the development of new immunosuppressive agents such as tacrolimus, mycophenolate mofetil, and sirolimus for specific indications. The ultimate goal of transplantation to achieve immunotolerance a waits future progress.
自从环孢素应用于小儿肝移植以来，患者和移植物的存活率有了显著提高：存活率达60%；急性排斥反应（60%）、激素抵抗性排斥反应（22%）和慢性排斥反应（4%）；感染（60%）；以及副作用（20%）。环孢素治疗的个体化补充了新型免疫抑制剂如他克莫司、霉酚酸酯和西罗莫司针对特定适应证的研发。移植实现免疫耐受的最终目标尚有待未来取得进展。
